MiNK Therapeutics, Inc.INKTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 80% recommend buying.

Consensus Rating

Buy

5 analysts·Limited coverage

80%

Rating Distribution

Strong Buy

00%

Buy

480%

Hold

120%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 216% higher.

Bear Case

$35.00

+216%

Consensus

$35.00

+216%

Bull Case

$35.00

+216%

Price Range5 analysts

Low

Consensus

High

$35.00

Current Target

Current Price

$11.07

Upside to Target

$23.93

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.61(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+3420.00%

EPS—

FY2028

Rev+650.00%

EPS—

FY2029

Rev+89.09%

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+2.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jul 15, 2025H.C. Wainwright

MiNK Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Target:$35.00

+21.7%from $28.75

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance